Literature DB >> 20581444

Checks and balances: E2F-microRNA crosstalk in cancer control.

Stephan Emmrich1, Brigitte M Pützer.   

Abstract

Extensive research on the E2F transcription factor family over the past decades has led to numerous insights that revealed the involvement of particularly E2F1 not only in proliferation and tumorigenesis but also in apoptosis and differentiation. Latest reports uncovered an essential role for oncogene signaling in regulating the balance of these events on the road to malignancy. Alterations in E2F functions coincide with poor prognosis in cancers, emphasizing their importance for the clinical cancer phenotype. An intriguing addition to the understanding of E2F crosstalks was the finding that their activity can be regulated by micro-RNAs (miRNAs) whose dysregulation has been implicated in malignancy. In turn, miRNAs themselves are targets of E2F family proteins establishing negative feedback loops. Since individual miRNAs may regulate hundreds of genes, these findings add a new challenging layer of complexity to the E2F network that possibly helps to make cell fate decisions. This review outlines our current understanding of the checks and balances of E2Fs and microRNAs in the context of a seemingly paradoxical role in cancer control.
© 2010 Landes Bioscience

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20581444     DOI: 10.4161/cc.9.13.12061

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  37 in total

Review 1.  MicroRNAs, wild-type and mutant p53: more questions than answers.

Authors:  Matthew Jones; Ashish Lal
Journal:  RNA Biol       Date:  2012-06-01       Impact factor: 4.652

Review 2.  Network calisthenics: control of E2F dynamics in cell cycle entry.

Authors:  Jeffrey V Wong; Peng Dong; Joseph R Nevins; Bernard Mathey-Prevot; Lingchong You
Journal:  Cell Cycle       Date:  2011-09-15       Impact factor: 4.534

Review 3.  Role of 3'-untranslated region translational control in cancer development, diagnostics and treatment.

Authors:  Andrii Vislovukh; Thaiz Rivera Vargas; Anna Polesskaya; Irina Groisman
Journal:  World J Biol Chem       Date:  2014-02-26

4.  E2F1 induces miR-224/452 expression to drive EMT through TXNIP downregulation.

Authors:  Susanne Knoll; Katharina Fürst; Bhavani Kowtharapu; Ulf Schmitz; Stephan Marquardt; Olaf Wolkenhauer; Hubert Martin; Brigitte M Pützer
Journal:  EMBO Rep       Date:  2014-10-23       Impact factor: 8.807

5.  Combined effects of E2F1 and E2F2 polymorphisms on risk and early onset of squamous cell carcinoma of the head and neck.

Authors:  Meixia Lu; Zhensheng Liu; Hongping Yu; Li-E Wang; Guojun Li; Erich M Sturgis; David G Johnson; Qingyi Wei
Journal:  Mol Carcinog       Date:  2012-02-17       Impact factor: 4.784

6.  YY1 promotes colorectal cancer proliferation through the miR-526b-3p/E2F1 axis.

Authors:  Zejun Fang; Hua Yang; Dan Chen; Xiaoying Shi; Qinqiu Wang; Chaoju Gong; Xi Xu; Hong Liu; Min Lin; Junxiao Lin; Chengfu Xu; Jimin Shao
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

7.  Functional variants at the miRNA binding sites of the E2F1 gene and its mRNA expression.

Authors:  Yunzhao Zhao; Lin Tang; Weiwei Nie; Zexing Wang; Xiaoxiang Guan
Journal:  Oncol Lett       Date:  2012-10-26       Impact factor: 2.967

8.  Transactivation of micrornA-320 by microRNA-383 regulates granulosa cell functions by targeting E2F1 and SF-1 proteins.

Authors:  Mianmian Yin; Xiaorong Wang; Guidong Yao; Mingrong Lü; Meng Liang; Yingpu Sun; Fei Sun
Journal:  J Biol Chem       Date:  2014-05-14       Impact factor: 5.157

9.  ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance.

Authors:  Julie Millour; Natalia de Olano; Yoshiya Horimoto; Lara J Monteiro; Julia K Langer; Rosa Aligue; Nabil Hajji; Eric W F Lam
Journal:  Mol Cancer Ther       Date:  2011-04-25       Impact factor: 6.261

Review 10.  The broken cycle: E2F dysfunction in cancer.

Authors:  Lindsey N Kent; Gustavo Leone
Journal:  Nat Rev Cancer       Date:  2019-06       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.